Hansa Biopharma AB Reports Positive Results for Imlifidase in Duchenne Muscular Dystrophy Treatment

Stockholm, August 4, 2025 — Hansa Biopharma AB, a biopharmaceutical company specializing in immunomodulatory enzymes, has announced positive results from a study involving the use of imlifidase in patients with Duchenne muscular dystrophy (DMD). The study, which was conducted prior to the administration of gene therapy, involved three patients who received imlifidase treatment.

According to the study, patients experienced a rapid reduction in IgG and anti-AAV antibodies following a dose of imlifidase. This reduction facilitated subsequent treatment with Sarepta’s gene therapy, Elevyidys. The safety profile of imlifidase was consistent with previous experiences, and no new safety signals were reported.

These findings represent the first results from a clinical trial where imlifidase was used to prepare patients for gene therapy in DMD. Hansa Biopharma’s CEO expressed optimism about the potential of imlifidase to improve the efficacy of gene therapies for rare diseases.

Financial Overview

As of July 31, 2025, Hansa Biopharma’s stock closed at 28.48 SEK on the Swedish Stock Exchange. The company’s market capitalization stands at 2.44 billion SEK. Over the past year, the stock has fluctuated between a high of 57.3 SEK on August 29, 2024, and a low of 19.58 SEK on April 6, 2025. The price-to-earnings ratio is currently -3.31, reflecting the company’s focus on research and development rather than immediate profitability.

Market Reaction

Following the announcement of the study results, Hansa Biopharma’s stock experienced a positive movement. On August 4, 2025, the OMXS30 index rose by 0.5%, and Hansa Biopharma’s shares were among those that increased in value. This positive market response highlights investor confidence in the company’s innovative approach to treating rare diseases.

Hansa Biopharma continues to focus on its mission to develop treatments for rare diseases and provide transplant rejection services, serving customers exclusively in Sweden. For more information, visit www.hansamedical.com .

This article provides a comprehensive overview of the recent developments and financial status of Hansa Biopharma AB, based on the latest news and fundamental information available.